Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

Open in Screener

CLNN

Clene Inc

May 14 • 04:00PM ET

0.3841

Dollar change -0.0067
Percentage change -1.71	%

Healthcare • Biotechnology • USA • NASD

Chart Stock Detail • Compare Perf. • Revenue • Dividends • Options Options Chain • Save to Portfolio • Create Alert

Held by: VTI VXF IWC

Index	-	P/E	-	EPS (ttm)	-0.48	Insider Own	42.71%	Shs Outstand	128.42M	Perf Week	-1.87%
Market Cap	49.33M	Forward P/E	-	EPS next Y	-0.28	Insider Trans	-0.11%	Shs Float	73.58M	Perf Month	15.90%
Income	-48.81M	PEG	-	EPS next Q	-0.07	Inst Own	9.35%	Short Float	0.92%	Perf Quarter	-9.20%
Sales	0.62M	P/S	79.56	EPS this Y	36.52%	Inst Trans	11.31%	Short Ratio	0.73	Perf Half Y	-14.64%
Book/sh	0.03	P/B	11.57	EPS next Y	7.49%	ROA	-114.91%	Short Interest	0.67M	Perf Year	-56.35%
Cash/sh	0.22	P/C	1.77	EPS next 5Y	-	ROE	-3702.24%	52W Range	0.25 - 1.09	Perf YTD	29.50%
Dividend Est.	-	P/FCF	-	EPS past 5Y	-18.22%	ROI	-303.78%	52W High	-64.76%	Beta	0.48
Dividend TTM	-	Quick Ratio	1.22	Sales past 5Y	50.93%	Gross Margin	-232.58%	52W Low	53.64%	ATR (14)	0.04
Dividend Ex-Date	-	Current Ratio	1.23	EPS Y/Y TTM	-15.29%	Oper. Margin	-6296.77%	RSI (14)	48.46	Volatility	10.48% 10.41%
Employees	85	Debt/Eq	7.62	Sales Y/Y TTM	12.73%	Profit Margin	-7873.23%	Recom	1.00	Target Price	5.00
Option/Short	Yes / Yes	LT Debt/Eq	2.77	EPS Q/Q	44.25%	Payout	-	Rel Volume	0.40	Prev Close	0.39
Sales Surprise	-55.08%	EPS Surprise	-12.50%	Sales Q/Q	-31.78%	Earnings	May 08 BMO	Avg Volume	928.43K	Price	0.38
SMA20	2.68%	SMA50	-2.96%	SMA200	-18.97%	Trades		Volume	368,053	Change	-1.71%

Date	Action	Analyst	Rating Change	Price Target Change
Oct-04-22	Downgrade	Oppenheimer	Outperform → Perform
Jul-18-22	Initiated	H.C. Wainwright	Buy	$16
May-02-22	Initiated	Canaccord Genuity	Buy	$10
Sep-28-21	Initiated	Oppenheimer	Outperform	$20

Today 08:00AM	Clene to Present at Upcoming May Conferences (GlobeNewswire)
May-10-24 07:30AM	Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday (InvestorPlace)
May-08-24 12:54PM	CLNN Stock Earnings: Clene Misses EPS, Misses Revenue for Q1 2024 (InvestorPlace)
08:55AM	Clene Inc. (CLNN) Reports Q1 Loss, Lags Revenue Estimates (Zacks)
08:00AM	Clene Reports First Quarter 2024 Financial Results and Recent Operating Highlights (GlobeNewswire)
06:00AM	Loading…
06:00AM	3 Speculative Penny Stocks Offering High-Upside Potential for Under a Buck (InvestorPlace)
May-01-24 08:30AM	IBN Announces From Lab to Launch Podcast Featuring Clene Inc. CEO Rob Etherington (GlobeNewswire)
Apr-16-24 04:01PM	Evidence for Clene's CNM-Au8 as a Treatment for Repair and Remyelination in Multiple Sclerosis Presented in the Emerging Science Session at the 2024 American Academy of Neurology Annual Meeting (GlobeNewswire) -6.46%
Mar-19-24 08:30AM	IBN Announces First in Human Podcast Featuring Clene Inc. CEO Rob Etherington (GlobeNewswire)
Mar-15-24 08:00AM	Clene Announces Peer-Reviewed Publication Characterizing the Protein Corona of the Investigational Neurodegenerative Disease Drug, CNM-Au8® (GlobeNewswire)
Mar-13-24 09:30AM	Clene Inc. (CLNN) Reports Q4 Loss, Tops Revenue Estimates (Zacks)
08:00AM	Clene Reports Full Year 2023 Financial Results and Recent Operating Highlights (GlobeNewswire)
Mar-07-24 08:00AM	Clene to Present at the 36th Annual ROTH Conference (GlobeNewswire)
Feb-29-24 08:00AM	Clene Presents Clinical Results of CNM-Au8 30mg Treatment From Visionary-MS Trial Long-Term Extension at Annual ACTRIMS Forum 2024 (GlobeNewswire) -7.28%
Feb-22-24 08:00AM	Clene Reports Significant Survival Benefit With CNM-Au8 Treatment in ALS EAP Compassionate Use Programs (GlobeNewswire)
02:30PM	Loading…
Feb-05-24 02:30PM	Clene Inc. announces positive results from CNM-Au8 results from MS trial (News Direct) -6.18%
Jan-24-24 08:30AM	Clene VISIONARY-MS Trial Data May Support CNM-Au8(R) as MS Treatment (NewMediaWire) +9.11%
Jan-10-24 09:00AM	Clene Announces Significant Positive Results from LTE VISIONARY-MS Trial (NewMediaWire)
Jan-08-24 07:00AM	Clene Reports Significant Improvement in Vision and Cognition With CNM-Au8 Treatment in VISIONARY-MS Trial Long-Term Open Label Extension (GlobeNewswire) +22.07%
Jan-03-24 04:25PM	Clene's Phase 2 REPAIR-PD and REPAIR-MD Trials Support Advancement to Phase 3 (NewMediaWire)
Dec-22-23 03:00PM	Clene Announces New Data from HEALEY ALS Platform Trial (NewMediaWire) -7.94%
Dec-21-23 07:46AM	FDA unconvinced by Clene's request for ALS therapy's accelerated approval tag (FierceBiotech.com) -38.83%
07:00AM	Clene Reports Reduction in Biomarker Plasma Neurofilament Light (NfL) Levels and Improved Survival With CNM-Au8 Treatment From HEALEY ALS Platform Trial Long-Term Open Label Extension (GlobeNewswire)
07:00AM	Clene Provides Update on ALS Clinical Development Meeting With FDA (GlobeNewswire)
Dec-19-23 09:00AM	How Clene CNM-Au8(R) Takes Advantage of Gold Nanocrystals to Target Neurodegenerative Disorders (NewMediaWire) +9.35%
Dec-15-23 03:00PM	Clene Lead Drug Candidate Featured in Peer-Reviewed Publication (NewMediaWire)
Dec-14-23 08:36AM	Clene Announces Peer-Reviewed Publication Describing CNM-Au8 Brain Target Engagement In Neurodegenerative Diseases (GlobeNewswire)
Dec-12-23 08:30AM	Clene's Long-Term Follow-Up Data Shows Significantly Improved Survival in ALS Patients (NewMediaWire) -6.45%
Dec-08-23 02:19PM	Nobel Prize in Chemistry's Spotlight on Nanotechnology Shines Light on Clene Efforts to Develop Catalytically Active Nanoparticles (NewMediaWire)
Nov-23-23 09:00AM	Clene Capitalizing on Promising Chemical and Therapeutic Properties of Nanocrystals (NewMediaWire)
08:30AM	Loading…
Nov-14-23 08:30AM	Clene Among Grant Awardees Selected to Advance Scientific Research on ALS (NewMediaWire) -6.78%
Nov-09-23 09:00AM	Clene Announces Q3 2023 Financial Results, Operating Highlights (NewMediaWire)
Nov-07-23 08:57AM	Clene Inc (CLNN) Reports Q3 2023 Financial Results: Significant Survival Benefits and $45. ... (GuruFocus.com) +8.02%
08:00AM	Clene Reports Third Quarter 2023 Financial Results and Operating Highlights (GlobeNewswire)
Oct-31-23 08:30AM	Clene Reports Improved Survival Status in ALS Patients Treated with CNM-Au8(R) on Follow-Up Analysis (NewMediaWire)
Oct-26-23 08:30AM	Clene Announces Four-Year Grant to Support Expanded Access Protocol for CNM-Au8 From NINDS (NewMediaWire)
Oct-19-23 08:30AM	Clene 'Innovates' Investigational Drug With Patented Nanotechnology (NewMediaWire)
Oct-17-23 08:30AM	Clene Applies Patented Nanotechnology to Development of CNM-Au8(R), Its Investigational Drug for ALS (NewMediaWire) -5.77%
Oct-11-23 09:00AM	Clene CEO Featured in Latest Episode of The Bell2Bell Podcast (NewMediaWire)
Oct-06-23 02:15PM	Clene Announces $45.1M NINDS Grant (NewMediaWire)
Oct-05-23 10:00AM	National Institutes of Health Awards $45.1 Million NINDS Grant for CNM-Au8 Study in ALS (GlobeNewswire) +9.98%
Sep-29-23 03:00PM	Clene Investigational Drug Focus of Study Published in Peer-Reviewed Journal (NewMediaWire)
08:30AM	Clene Inc. Is 'One to Watch' (NewMediaWire)
Sep-28-23 08:00AM	Clene Announces Peer-Reviewed Publication Describing CNM-Au8 Catalytic Neuroprotective Mechanism of Action (GlobeNewswire) -5.30%
Sep-27-23 09:00AM	Clene Releases Significant Long-Term Survival Improvement Data from ALS Trial (NewMediaWire)
Sep-25-23 04:00PM	Clene to Present at Cantor Fitzgerald Annual Global Healthcare Conference (GlobeNewswire)
07:00AM	Clene Reports Significant Long-Term Survival Improvement From CNM-Au8 Treatment in HEALEY ALS Platform Trial Compared to PRO-ACT Historical Controls (GlobeNewswire)
Aug-30-23 08:20AM	Clene to Present at Upcoming September Conferences (GlobeNewswire) +7.94%
Aug-29-23 07:00AM	Clene Reports Significantly Improved Survival Benefit of 19.3 Months and Significantly Delayed Clinical Worsening in Rescue-Als Open-Label Extension Two Year Follow-Up (GlobeNewswire)
Aug-14-23 08:00AM	Clene Reports Second Quarter 2023 Financial Results and Operating Highlights (GlobeNewswire)
Aug-02-23 07:00AM	Clene to Present at the Canaccord Genuity 43rd Annual Growth Conference (GlobeNewswire)
Jun-28-23 11:19AM	Insiders Pour Millions Into These 2 Strong Buy Stocks Heres Why You Might Want to Steer Toward Them Too (TipRanks) +5.14%
07:13AM	Daily Vickers Top Buyers & Sellers for 06/28/2023 (Argus Research)
Jun-26-23 08:00AM	Clene Announces Publication of Phase 2 CNM-Au8® Clinical Data for the Treatment of ALS in LANCETs eClinicalMedicine (GlobeNewswire)
Jun-21-23 09:20AM	Clene Welcomes New Shareholder Base and Announces Closing of Underwritten Public Offering of $40 Million (GlobeNewswire) -8.00%
07:20AM	Daily Vickers Top Buyers & Sellers for 06/21/2023 (Argus Research)
Jun-16-23 08:00AM	Clene Announces Pricing of $40 Million Public Offering (GlobeNewswire) -18.85%
Jun-15-23 04:38PM	Clene Announces Launch of Proposed Public Offering (GlobeNewswire)
04:29PM	Clenes CNM-Au8® Shows Statistically Significant Difference in Plasma Neurofilament Light (NfL) levels in the HEALEY ALS Platform Trial (GlobeNewswire)
07:00AM	Clene to Participate in the Maxim Group Virtual Healthcare Conference (GlobeNewswire)
May-25-23 08:00AM	Clene Awarded Grant From National Multiple Sclerosis Society to Advance Development of CNM-Au8® in Non-Active Progressive Multiple Sclerosis (GlobeNewswire)
May-12-23 04:00PM	Clene Reports First Quarter 2023 Financial Results and Recent Operating Highlights (GlobeNewswire)
Apr-25-23 04:05PM	ALS and MS Clinical Data from Clenes CNM-Au8® Featured in Multiple Presentations at the 2023 American Academy of Neurology Annual Meeting (GlobeNewswire)
Apr-11-23 08:00AM	Clene Announces the Plenary Presentations of MS and ALS Data Supporting the Efficacy and Safety of CNM-Au8® at the 2023 American Academy of Neurology Annual Meeting (GlobeNewswire)
Mar-16-23 09:46AM	Clene Appoints Neurology Expert to Executive Team (GlobeNewswire)
Mar-13-23 07:00AM	Clene Reports Full Year 2022 Financial Results and Recent Operating Highlights (GlobeNewswire) +7.94%
Mar-09-23 06:30AM	CNM-Au8® Associated With Delayed Time to Key Clinical Progression Events at Six Months Supporting a Survival Benefit in the Healey ALS Platform Trial (GlobeNewswire)
Mar-08-23 04:10PM	Clene to Announce New CNM-Au8® Data From the Healey ALS Platform Trial (GlobeNewswire)
Mar-07-23 08:00AM	Clene Nanomedicine to Participate in Roths 35th Annual Healthcare Conference and Renmark Virtual Non-Deal Roadshow Series (GlobeNewswire)
Mar-06-23 07:00AM	New Data Show CNM-Au8® Preserved ALS Patient Function and Slowed Disease Progression in the Open-Label Extension of the Phase 2 RESCUE-ALS Trial (GlobeNewswire) +6.67%
Feb-27-23 07:00AM	Clene Announces Updated VISIONARY-MS Phase 2 Trial Data Presented at 2023 ACTRIMS Forum Show CNM-Au8® Demonstrated Significant Improvements in Clinical Outcomes, Brain Structure, and Visual System (GlobeNewswire)
Feb-13-23 07:00AM	Clene Reports New Data from the VISIONARY-MS Phase 2 Study in Multiple Sclerosis Demonstrating CNM-Au8® Treatment Improved Brain Neuronal Structural Integrity (GlobeNewswire) +7.41%
Jan-11-23 08:00AM	Clene Nanomedicine Announces Participation in Renmark Virtual Non-Deal Roadshow Series on January 18 and January 23 (GlobeNewswire)
Dec-27-22 04:01PM	Clene Nanomedicine Reports Topline Results of Phase 2 COVID-19 Study of CNM-ZnAg (GlobeNewswire)
Dec-12-22 08:00AM	Clene Announces Closing of $5 Million Debt Facility from the State of Maryland (GlobeNewswire)
Nov-28-22 08:00AM	VISIONARY-MS Trial Results Featured in Platform Presentation at PACTRIMS 2022: CNM-Au8® Demonstrated Global Neurological Improvement in Stable MS Patients as Adjunct to Background Disease Modifying Therapies (GlobeNewswire) +5.88%
Nov-07-22 08:00AM	Clene Reports Third Quarter 2022 Financial Results and Recent Operating Highlights (GlobeNewswire) -12.69%
Oct-31-22 08:00AM	Clene Announces $10.8 Million Registered Direct Offering and $5 Million Debt Facility from the State of Maryland (GlobeNewswire)
Oct-03-22 08:00AM	Clene Reports Topline Results Demonstrating Survival Signal for CNM-Au8® in Healey ALS Platform Trial (GlobeNewswire) -28.21%
Sep-30-22 04:12PM	Clene to Report HEALEY ALS Platform Trial Topline Results on Monday, October 3 (GlobeNewswire)
Sep-21-22 07:00AM	Clene Nanomedicine Presents Updated Long-Term Survival Data from RESCUE-ALS Participants at 2022 AANEM Scientific Conference (GlobeNewswire)
Aug-30-22 07:00AM	Clene to Present at Upcoming September Investor Conferences (GlobeNewswire)
Aug-15-22 07:00AM	Clene Reports Second Quarter 2022 Financial Results and Recent Operating Highlights (GlobeNewswire) +5.80%
07:00AM	Clene Reports Positive Topline Results for CNM-Au8® in the Phase 2 VISIONARY-MS Trial in Multiple Sclerosis (GlobeNewswire)
Aug-12-22 04:01PM	Clene to Host VISIONARY-MS Results Call and Webcast on August 15 (GlobeNewswire)
Jul-19-22 07:00AM	Clene Receives Positive EMA Opinion on Orphan Drug Designation for CNM-Au8® for the Treatment of ALS (GlobeNewswire)
Jul-14-22 07:00AM	Clene Reports Significantly Decreased Mortality in RESCUE-ALS Long-Term Open Label Extension Trial (GlobeNewswire) +43.40%
Jun-27-22 07:00AM	Clene to Participate in Panel Discussion About Innovations in ALS Presented by Maxim Group and Hosted by M-Vest on June 28 (GlobeNewswire) +6.90%
Jun-02-22 07:00AM	Clene Salutes Collaboration of ALS Community and Major League Baseball on Lou Gehrig Day (GlobeNewswire) +8.30%
Jun-01-22 07:00AM	New Data from Clenes RESCUE-ALS Study to be Presented at 2022 ENCALS Meeting (GlobeNewswire) +5.05%
May-19-22 07:30AM	Clene Receives $3 Million Loan from State of Maryland to Support Development of Commercial Manufacturing Facility (GlobeNewswire) +8.56%
May-16-22 08:00AM	Clene to Present at Upcoming Investor Conferences (GlobeNewswire)
May-09-22 08:00AM	Clene Reports First Quarter 2022 Financial Results and Recent Operating Highlights (GlobeNewswire) -13.53%
May-04-22 11:29AM	These 2 Penny Stocks Can Deliver Over 200% Gains, Says Canaccord (TipRanks) +17.60%
Apr-01-22 07:00AM	Updated Interim Data from Clene Nanomedicines RESCUE-ALS Open-Label Extension Study to be Presented in Emerging Science Program at 2022 AAN Annual Meeting (GlobeNewswire) -5.08%
Mar-14-22 07:00AM	Clene Nanomedicine Presents Updated Clinical Data from Phase 2 RESCUE-ALS and REPAIR trials and Preclinical ALS data at 2022 MDA Clinical & Scientific Conference (GlobeNewswire)
Mar-11-22 07:00AM	Clene Reports Full Year 2021 Financial Results and Recent Operating Highlights (GlobeNewswire)
Mar-03-22 07:00AM	Clene Nanomedicine to Present at Upcoming Investor Conferences (GlobeNewswire)
Feb-24-22 07:00AM	Clene Nanomedicine Presents Data from Two Phase 2 Multiple Sclerosis Trials at ACTRIMS Forum 2022 (GlobeNewswire) +7.17%
Feb-18-22 07:00AM	Clene Nanomedicine to Present Data from Phase 2 Multiple Sclerosis Programs at ACTRIMS Forum 2022 (GlobeNewswire)

Clene, Inc. is a clinical-stage biopharmaceutical company, which focuses on the discovery, development, and commercialization of novel clean-surfaced nanotechnology therapeutics. It offers a nanotechnology drug platform for the development of a new class of orally administered neurotherapeutic drugs. The company was founded in 2013 and is headquartered in Salt Lake City, UT.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
General Resonance LLC	10% Owner	May 01 '24	Sale	0.40	13,000	5,148	15,313,712	May 08 12:16 PM
General Resonance LLC	10% Owner	Apr 30 '24	Sale	0.42	13,000	5,416	15,326,712	May 08 12:16 PM
General Resonance LLC	10% Owner	Apr 24 '24	Sale	0.33	10,000	3,278	15,349,712	May 01 05:13 PM
General Resonance LLC	10% Owner	Apr 09 '24	Sale	0.39	22,500	8,674	15,428,212	Apr 16 09:38 AM
MATLIN DAVID J	Director	Nov 10 '23	Buy	0.41	250,002	102,501	7,043,686	Nov 13 07:48 AM
Stevens John Henry	Director	Jun 26 '23	Buy	0.80	316,455	253,164	800,204	Jun 27 02:13 PM
Etherington Robert Dee	Chief Executive Officer	Jun 26 '23	Buy	0.81	25,000	20,250	25,000	Jun 27 08:07 AM
Ugwumba Chidozie	Resigned as director 2/15/2023	Jun 16 '23	Buy	0.80	7,500,000	6,000,000	13,018,908	Sep 08 04:33 PM
Mosca Alison	Director	Jun 16 '23	Buy	0.80	2,394,375	1,915,500	3,238,375	Jun 20 11:02 AM
MATLIN DAVID J	Director	Jun 16 '23	Buy	0.80	1,500,000	1,200,000	6,793,684	Jun 20 07:57 AM
Gay Jonathon	Director	Jun 16 '23	Buy	0.80	105,625	84,500	105,625	Jun 20 09:50 AM

Open in Screener

PHGE

BiomX Inc

May 14 • 04:00PM ET

0.3460

Dollar change +0.0058
Percentage change 1.70	%

Healthcare • Biotechnology • Israel • AMEX

Chart Stock Detail • Compare Perf. • Revenue • Dividends • Options Options Chain • Save to Portfolio • Create Alert

Index	-	P/E	-	EPS (ttm)	-0.57	Insider Own	64.83%	Shs Outstand	45.98M	Perf Week	-13.50%
Market Cap	19.11M	Forward P/E	-	EPS next Y	-0.22	Insider Trans	-0.03%	Shs Float	19.42M	Perf Month	15.29%
Income	-26.17M	PEG	-	EPS next Q	-0.07	Inst Own	0.41%	Short Float	0.87%	Perf Quarter	56.17%
Sales	0.00M	P/S	-	EPS this Y	50.98%	Inst Trans	-0.16%	Short Ratio	0.06	Perf Half Y	-11.28%
Book/sh	0.07	P/B	5.16	EPS next Y	12.00%	ROA	-39.47%	Short Interest	0.17M	Perf Year	24.01%
Cash/sh	0.29	P/C	1.20	EPS next 5Y	-	ROE	-216.99%	52W Range	0.19 - 0.86	Perf YTD	23.57%
Dividend Est.	-	P/FCF	-	EPS past 5Y	-28.31%	ROI	-223.25%	52W High	-59.53%	Beta	1.33
Dividend TTM	-	Quick Ratio	1.58	Sales past 5Y	0.00%	Gross Margin	-	52W Low	85.42%	ATR (14)	0.05
Dividend Ex-Date	-	Current Ratio	1.58	EPS Y/Y TTM	39.69%	Oper. Margin	0.00%	RSI (14)	47.37	Volatility	11.93% 14.37%
Employees	71	Debt/Eq	4.90	Sales Y/Y TTM	-	Profit Margin	-	Recom	1.00	Target Price	3.00
Option/Short	No / Yes	LT Debt/Eq	2.81	EPS Q/Q	39.21%	Payout	-	Rel Volume	0.01	Prev Close	0.34
Sales Surprise	-	EPS Surprise	45.45%	Sales Q/Q	-	Earnings	Apr 03 BMO	Avg Volume	2.68M	Price	0.35
SMA20	-3.09%	SMA50	-4.71%	SMA200	4.75%	Trades		Volume	31,735	Change	1.70%

Date	Action	Analyst	Rating Change	Price Target Change
Apr-15-21	Initiated	Ladenburg Thalmann	Buy	$25

May-06-24 07:00AM	BiomX to Present at the 2024 RBC Capital Markets Global Healthcare Conference (GlobeNewswire) +6.28%
Apr-23-24 08:00AM	BiomX to Present Data from Phase 1b/2a Study of BX004 for the Treatment of Cystic Fibrosis Patients with Chronic Pulmonary Infections at the 34th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID 2024) (GlobeNewswire) +17.42%
Apr-18-24 08:00AM	BiomX Announces the Appointment of Susan Blum to its Board of Directors (GlobeNewswire) +5.61%
Apr-05-24 09:55AM	Here's Why BiomX (PHGE) Is a Great 'Buy the Bottom' Stock Now (Zacks)
Apr-04-24 07:49AM	BiomX Announces Compliance with NYSE Guidelines on Audit Opinion Disclosure (GlobeNewswire) +8.57%
06:30AM	Loading…
Apr-03-24 06:30AM	BiomX Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update (GlobeNewswire) -8.90%
Mar-27-24 06:30AM	BiomX to Host Fourth Quarter and Full Year 2023 Financial Results Conference Call and Webcast on April 3rd, 2024 (GlobeNewswire) +6.07%
Mar-19-24 05:00AM	Telum Therapeutics appoints Dr. Subhendu Basu as CEO (PR Newswire)
Mar-18-24 06:30AM	BiomX Announces Closing of the Acquisition of Adaptive Phage Therapeutics and Concurrent $50 Million Financing (GlobeNewswire)
Mar-06-24 07:30AM	BiomX Announces Entry into Merger Agreement with Adaptive Phage Therapeutics and Concurrent $50 Million Financing (GlobeNewswire) +197.66%
Jan-04-24 08:00AM	BiomX Receives Orphan Drug Designation from the U.S. Food and Drug Administration for BX004 for the Treatment of Chronic Pulmonary Infection Caused by Pseudomonas aeruginosa in Patients with Cystic Fibrosis (GlobeNewswire)
Nov-30-23 04:15PM	BiomX to Host Virtual Key Opinion Leader (KOL) Event to Review the Positive Results from Part 2 of Phase 1b/2a Trial of BX004 in Cystic Fibrosis Patients with Chronic Pseudomonas aeruginosa Infections on December 4, 2023 (GlobeNewswire) -13.67%
Nov-29-23 06:30AM	BiomX Announces Positive Topline Results from Part 2 of the Phase 1b/2a Trial Evaluating BX004 for Treatment of Chronic Pulmonary Infections in Patients with Cystic Fibrosis (GlobeNewswire) -46.43%
Nov-14-23 06:30AM	BiomX Reports Third Quarter 2023 Financial Results and Provides Business Update (GlobeNewswire)
Oct-27-23 08:00AM	BiomX to Present Data from Ongoing Phase 1b/2a Study Evaluating BX004 for the Treatment of Chronic Pseudomonas aeruginosa Pulmonary Infections in Patients with Cystic Fibrosis at the 37th Annual North American Cystic Fibrosis Conference (GlobeNewswire)
08:00AM	Loading…
Oct-18-23 08:00AM	BiomX Announces the Appointment of Edward L. Williams to its Board of Directors (GlobeNewswire)
Oct-04-23 06:34AM	BiomX Announces Completion of Patient Dosing in Part 2 of the Phase 1b/2a Study Evaluating BX004 for Treatment of Chronic Pulmonary Infections in Patients with Cystic Fibrosis (GlobeNewswire)
Sep-07-23 09:00AM	BiomX to Present Data from Ongoing Phase 1b/2a Study Evaluating BX004 for the Treatment of Chronic Pseudomonas aeruginosa Pulmonary Infections in Patients with Cystic Fibrosis at the European Respiratory Society (ERS) International Congress 2023 (GlobeNewswire)
Sep-06-23 04:05PM	BiomX to Present at H.C. Wainwright 25th Annual Global Investment Conference (GlobeNewswire)
Aug-09-23 06:30AM	BiomX Reports Second Quarter 2023 Financial Results and Provides Business Update (GlobeNewswire) -9.29%
Aug-02-23 04:30PM	BiomX to Host Second Quarter 2023 Financial Results Conference Call and Webcast on August 9th, 2023 (GlobeNewswire)
Jun-08-23 05:00PM	NYSE American Initiates Delisting Proceedings for BiomX Warrants (GlobeNewswire)
May-31-23 03:00AM	BiomX to Present Part 1 Data from Phase 1b/2a Study Evaluating BX004 for the Treatment of Chronic Pseudomonas aeruginosa Pulmonary Infections in Patients with Cystic Fibrosis During Late-Breaking Science Session at the 46th European Cystic Fibrosis Conference (ECFC) (GlobeNewswire) +13.56%
May-15-23 06:30AM	BiomX Reports First Quarter 2023 Financial Results and Provides Business Update (GlobeNewswire) +7.17%
May-12-23 08:00AM	BiomX Announces the Appointments of Jason M. Marks and Michael E. Dambach to Board of Directors (GlobeNewswire) +9.97%
May-08-23 06:30AM	BiomX to Host First Quarter 2023 Financial Results Conference Call and Webcast on May 15th, 2023 (GlobeNewswire)
May-05-23 06:30AM	BiomX Announces Second Closing of $7.5 Million Private Placement (GlobeNewswire) +7.18%
Mar-29-23 06:30AM	BiomX Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update (GlobeNewswire)
Mar-27-23 07:00AM	BiomX to Host Fourth Quarter and Full Year 2022 Financial Results Conference Call and Webcast on March 29th, 2023 (GlobeNewswire) +7.00%
Feb-22-23 06:35AM	BiomX Announces $7.5 Million Private Placement (GlobeNewswire)
06:30AM	Loading…
06:30AM	BiomX Announces Positive Results from Part 1 of the Phase 1b/2a Study Evaluating BX004 for Treatment of Chronic Pulmonary Infections in Patients with Cystic Fibrosis (GlobeNewswire)
Nov-29-22 09:10AM	BiomX To Present at H.C. Wainwright 1st Annual Investor Conference on Bacteriophage (GlobeNewswire) +6.50%
Nov-09-22 06:30AM	BiomX Reports Third Quarter 2022 Financial Results and Provides Business Update (GlobeNewswire)
Nov-02-22 09:00AM	BiomX to Host Third Quarter 2022 Financial Results Conference Call and Webcast on November 9, 2022 (GlobeNewswire)
Sep-11-22 07:22AM	BiomX To Present at H.C. Wainwright 24th Annual Global Investment Conference (Business Wire)
Aug-10-22 06:30AM	BiomX Reports Second Quarter 2022 Financial Results and Provides Business Update (Business Wire) -6.41%
Aug-07-22 03:17AM	BiomX to Host Second Quarter 2022 Financial Results Conference Call and Webcast on August 10, 2022 (Business Wire)
Aug-04-22 11:20AM	BiomX Announces Publication in Cell of Research Demonstrating Proof-of-Concept Assessment of Orally Administered Phage Treatment in Preclinical Model of Inflammatory Bowel Disease (Business Wire) +6.18%
Jul-06-22 01:45AM	BiomX Announces Voluntary Delisting from the Tel Aviv Stock Exchange (Business Wire) -5.37%
Jun-28-22 06:30AM	Boehringer Ingelheim and BiomX Collaborate to Discover Inflammatory Bowel Disease Microbiome Biomarkers (Business Wire)
Jun-27-22 06:30AM	BiomX Announces Dosing of the First Two Patients in Phase 1b/2a Study of BX004 for Treatment of Chronic Respiratory Infections in Patients with Cystic Fibrosis (Business Wire)
May-24-22 01:52AM	BiomX Announces Corporate Restructuring (Business Wire) +8.74%
May-20-22 08:00AM	BiomX Announces Publication in the Journal, Bioinformatics (Business Wire)
May-11-22 06:30AM	BiomX Reports First Quarter 2022 Financial Results and Provides Business Update (Business Wire) -6.09%
May-06-22 07:00AM	BiomX to Host Key Opinion Leader Event on BX004 for Treatment of Pseudomonas Aeruginosa Infections in Cystic Fibrosis Patients (Business Wire)
May-05-22 08:00AM	BiomX to Host First Quarter 2022 Financial Results Conference Call and Webcast on May 11, 2022 (Business Wire)
Mar-30-22 06:30AM	BiomX Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Business Update (Business Wire) +14.38%
Mar-23-22 08:00AM	BiomX to Host Fourth Quarter and Full Year 2021 Financial Results Conference Call and Webcast on March 30, 2022 (Business Wire)
Feb-24-22 08:00AM	BiomX Presenting at Three Upcoming Investor Conferences (Business Wire)
Jan-04-22 07:00AM	BiomX Announces Therapeutics Development Award of up to $5 Million from the Cystic Fibrosis Foundation (Business Wire)
Nov-17-21 08:00AM	BiomX Presenting at Two Upcoming Conferences in November (GlobeNewswire)
Nov-15-21 06:00AM	BiomX Reports Third Quarter 2021 Financial Results and Provides Business Update (GlobeNewswire)
Nov-09-21 08:00AM	BiomX to Host Third Quarter 2021 Financial Results Conference Call and Webcast on November 15, 2021 (GlobeNewswire)
Oct-25-21 10:00AM	Down 28.1% in 4 Weeks, Here's Why BiomX Inc. (PHGE) Looks Ripe for a Turnaround (Zacks)
Oct-18-21 07:00AM	BiomX Reports Topline Results of Phase 2 Cosmetic Acne Study (GlobeNewswire) -12.35%
Oct-13-21 07:00AM	BiomX Announces Agreement with Maruho Co., Ltd. for Atopic Dermatitis Product Candidate BX005 (GlobeNewswire) -5.15%
Sep-02-21 04:05PM	BiomX to Present at Upcoming September Investor Conferences (GlobeNewswire) -7.29%
Aug-16-21 06:30AM	BiomX Reports Second Quarter 2021 Financial Results and Provides Business Update (GlobeNewswire) -7.65%
Aug-12-21 08:00AM	BiomX to Host Second Quarter 2021 Financial Results Conference Call and Webcast on August 16, 2021 (GlobeNewswire)
Jul-26-21 08:13AM	BiomX Inc. Announces $15 Million Registered Direct Offering (GlobeNewswire) +9.45%
Jun-14-21 06:30AM	BiomX Presents Preclinical Results With BX005 for Atopic Dermatitis at the Revolutionizing Atopic Dermatitis 2021 Virtual Conference and the International Conference on Phage Therapy and Bacteriophages (Business Wire)
Jun-09-21 06:30AM	BiomX to Present Preclinical Results with BX004 in Cystic Fibrosis at the 44th European Cystic Fibrosis Conference (Business Wire)
May-25-21 10:46AM	BiomX Reports Q1 Earnings; Shares Jump 6% (SmarterAnalyst)
May-24-21 06:30AM	BiomX Reports First Quarter 2021 Financial Results and Provides Business Updates (Business Wire)
06:15AM	BiomX Inc to Host Earnings Call (ACCESSWIRE)
May-18-21 08:00AM	BiomX To Host Key Opinion Leader Event on BX003 for the Treatment of Inflammatory Bowel Disease (GlobeNewswire)
06:30AM	BiomX to Host First Quarter 2021 Financial Results Conference Call and Webcast on May 24, 2021 (Business Wire)
Apr-20-21 07:00AM	BiomX to Present at Upcoming April Investor Events (Business Wire)
Mar-31-21 06:30AM	BiomX Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Business Update (Business Wire)
05:45AM	BiomX Inc to Host Earnings Call (ACCESSWIRE)
Mar-24-21 06:30AM	BiomX to Report Fourth Quarter and Full Year 2020 Financial Results on March 31, 2021 (Business Wire)
Mar-02-21 07:00AM	BiomX Announces Dosing of First Subject in Phase 2 Study of BX001 for Acne-Prone Skin (Business Wire) +10.77%
Mar-01-21 07:00AM	BiomX to Present at Upcoming March Investor Conferences (Business Wire) +7.29%
Feb-02-21 06:30AM	BiomX Announces Positive Results of a Phase 1a Pharmacokinetic Study for Inflammatory Bowel Disease/Primary Sclerosing Cholangitis (IBD/PSC) Evaluating Delivery of Oral BX002 Phage Therapy (Business Wire)
Jan-04-21 06:30AM	BiomX to Present at Upcoming January Investor Conferences (Business Wire)
Dec-09-20 04:30PM	BiomX Announces Preclinical Results of Analysis of Patient Samples and Engineering of Phage for Therapeutic Applications in Colorectal Cancer (Business Wire)
Dec-02-20 06:21PM	Here is What Hedge Funds Think About BiomX Inc. (PHGE) (Insider Monkey) -5.06%
Nov-16-20 06:30AM	BiomX Presents Preclinical Results of Phage Targeting Klebsiella pneumoniae for Primary Sclerosing Cholangitis and Inflammatory Bowel Disease (Business Wire)
Nov-12-20 06:30AM	BiomX Reports Third Quarter 2020 Financial Results and Announces Expanded Portfolio of Phage Therapy Candidates (Business Wire)
06:15AM	BiomX Inc to Host Earnings Call (ACCESSWIRE)
Nov-10-20 04:30PM	BiomX to Present at Upcoming November Investor Conferences (Business Wire)
Nov-05-20 06:30AM	BiomX to Report Third Quarter 2020 Financial Results on Nov. 12, 2020 (Business Wire)
Nov-04-20 06:30AM	BiomX Announces Dosing of First Subject in Phase 1a Study of BX002 Phage Therapy for Inflammatory Bowel Disease (Business Wire)
Oct-21-20 06:30AM	BiomX Presents Preclinical Data on Phage Targeting Multidrug Resistant Klebsiella pneumoniae Bacteria at the Infectious Disease Society of America (IDSA) IDWeek Conference 2020 (Business Wire)
Oct-05-20 06:30AM	BiomX Appoints Paul Sekhri and Alan Moses, M.D., to Board of Directors (Business Wire)
Sep-10-20 04:30PM	BiomX to Present at Upcoming September Investor Conferences (Business Wire)
Sep-02-20 06:30AM	BiomX Enters Collaboration with Boehringer Ingelheim with the Goal of Discovering Microbiome-Based Biomarkers for Inflammatory Bowel Disease (Business Wire)
Aug-13-20 06:30AM	BiomX Reports Second Quarter 2020 Financial Results and Provides Business Update (Business Wire) -16.42%
Aug-12-20 12:17PM	Is BiomX Inc. (NYSEMKT:PHGE) Popular Amongst Institutions? (Simply Wall St.) -7.75%
Aug-06-20 07:00AM	BiomX to Report Second Quarter 2020 Financial Results on Aug. 13, 2020 (Business Wire)
May-14-20 06:30AM	BiomX Reports First Quarter 2020 Financial Results and Provides Business Update (Business Wire) -8.48%
May-11-20 05:00PM	BiomX to Announce First Quarter 2020 Financial Results on May 14, 2020 (Business Wire)
Apr-07-20 04:05PM	BiomX Announces Date of 2020 Annual Meeting of Stockholders (Business Wire) -11.28%
Mar-31-20 06:30AM	BiomX Announces Positive Topline Data from Phase 1 Study for Lead Candidate BX001 for Acne-Prone Skin (Business Wire) -9.33%
Mar-26-20 06:30AM	BiomX Reports Full Year 2019 Financial Results and Provides Business Update (Business Wire) +7.45%
Mar-20-20 08:00AM	BiomX Discloses Acne Pre-clinical Data Planned for 2020 AAD Annual Meeting (Business Wire)
Feb-17-20 07:00AM	BiomX To Present Pre-clinical Data at the Plenary Session of the AACR Microbiome, Viruses, and Cancer Conference (Business Wire)
Dec-02-19 07:30AM	BiomX Announces Completion of Enrollment for Double-Blind, Placebo-Controlled Clinical Study of BX001 in Acne-Prone Skin (Business Wire)
Nov-12-19 07:30AM	BiomX Presents Preclinical Results of its Phage Therapy Program Targeting Primary Sclerosing Cholangitis (Business Wire) -5.53%
07:25AM	Stone Street Group Initiates Coverage On BiomX Inc. (PR Newswire)

BiomX, Inc. operates as a clinical-stage microbiome company, which engages in the development of both natural and engineered phage cocktails designed to target and destroy harmful bacteria in chronic diseases, such as cystic fibrosis and atopic dermatitis. Its product pipelines include BX004 and BX005, which are treatments for cystic fibrosis and atopic dermatitis respectively. The company was founded in March 2015 and is headquartered in Ness Ziona, Israel.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Oron Assaf	Chief Business Officer	Nov 29 '23	Sale	0.37	10,914	4,072	0	Dec 01 04:46 PM
Oron Assaf	Chief Business Officer	May 22 '23	Buy	0.27	3,192	872	10,914	May 24 06:03 AM
Oron Assaf	Chief Business Officer	May 19 '23	Buy	0.28	6,521	1,832	7,722	May 22 04:01 PM
Oron Assaf	Chief Business Officer	May 18 '23	Buy	0.27	1,201	328	1,201	May 22 04:01 PM

affiliate • advertise • toggle light mode • contact • privacy • help
do not sell my data • privacy settings

CLNN

Clene Inc

PHGE

BiomX Inc

Upgrade your FINVIZ experience